Brief: Hutchmed (China) Says Ipsen Initiates Market Withdrawal And Recall Of Tazverik In China
March 9 (Reuters) - HUTCHMED (China) Ltd 0013.HK: IPSEN INITIATES MARKET WITHDRAWAL AND RECALL OF TAZVERIK IN CHINA WITHDRAWS AND RECALLS TAZVERIK IN CHINA, HONG KONG, MACAU; ENDS ALL CLINICAL TRIALS ІPSEN HAS INFORMED HUTCHMED THAT IT IS VOLUNTARILY WITHDRAWING TAZVERІK IN US Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsKras: EGFR-Antibody licensing deal with GSK closes
Brief: Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals